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Graph	   1.	   Sca+er	   plot	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   k e y	  
transcrip7on	   factor	  
early	   growth	   response	  
1	   ( E G R -­‐ 1 )	   i s	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mRNA	   level	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and	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   adjacent	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   normal	  
p r o s t a t e	   7 s s u e s .	  
(Haaland	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   et	   al.	  
2009;	   Interna7onal	  




•  Prostate	  cancer	  is	  the	  second	  most	  common	  cancer	  in	  American	  men	  with	  about	  230,000	  
new	  diagnoses	  and	  30,000	  deaths	  annually.	  Diagnosis	  by	  biopsy	  is	  hampered	  by	  a	  30-­‐50%	  
false-­‐negaSve	  rate	  due	  to	  small	  and	  easily	  missed	  cancer	  foci.	  
•  Field	   cancerizaSon	   denotes	   geneSc	   and/or	   biochemical	   molecular	   alteraSons	   in	  
phenotypically	  normal	  cells	  residing	  in	  histologically	  normal	  Sssues	  adjacent	  to	  prostate	  
tumors	  and	  may	  represent	  a	  temporal	  record	  of	  pathways	  underlying	  oncogenesis.	  
HYPOTHESIS	  and	  OBJECTIVE	  
	  
•  Hypothesis:	  EGR-­‐1	  protein	  expression	  will	  be	   similarly	  elevated	  
in	   cancerous	   and	   histologically	   normal	   adjacent	   Sssues,	   which	  
will	   support	   the	   concept	   of	   ﬁeld	   cancerizaSon.	   We	   further	  
hypothesize	   that	  markers	  of	  ﬁeld	   cancerizaSon,	   such	  as	  EGR-­‐1,	  
could	   serve	  as	  biomarkers	  of	  disease	  and	   improve	  early	   cancer	  
detecSon	  (diagnosis)	  at	  the	  Sme	  of	  biopsy.	  
	  
•  ObjecSve:	  Determine	  expression	  of	  EGR-­‐1	  protein	   in	  malignant	  
and	  adjacent	  Sssues.	  
EXPERIMENTAL	  METHODS	  
	  
Tissue	  Samples:	  Human	  prostate	  Sssues	  containing	  cancer	  cells	  (malignant)	  and	  matched	  adjacent	  Sssues	  devoid	  
of	  cancer	  cells	  (benign)	  from	  prostatectomies	  and	  matched	  biopsies	  were	  obtained	  from	  the	  CooperaSve	  Prostate	  
Cancer	  Tissue	  Resource	   (CPCTR).	  The	  present	  work	   is	  approved	  by	  Chapman	  University	   IRB	  protocol	  #1415H024	  
under	  biosafety	  level	  2	  (BSL2)	  approved	  pracSces	  as	  per	  InsStuSonal,	  State,	  and	  Federal	  laws.	  
	  
Immunoﬂuorescence	  Microscopy:	  Immunoﬂuorescence	  microscopy	  was	  performed	  using	  rabbit	  anS-­‐human	  EGR-­‐1	  
anSbodies,	  unspeciﬁc	  control	  IgG,	  and	  goat	  anS-­‐rabbit	  Alexa	  Fluor	  488	  (green)	  conjugated	  anSbodies.	  Fluorescent	  
DAPI	  dye	  (blue)	  was	  used	  to	  visualize	  cell	  nuclei.	  
	  
QuanSﬁcaSon:	   QuanStaSve	   analysis	   (pixel	   densitometry)	   was	   performed	   using	   ImageJ64	   (provided	   by	   the	  
NaSonal	  InsStutes	  of	  Health)	  and	  graphs	  were	  generated	  using	  Microsoj	  Excel	  and	  JumpIn	  sojware.	  Two	  signal	  
acquisiSon	  modes	  were	  applied:	  Whole	  image	  analysis	  and	  region	  of	  interest	  analysis.	  
RESULTS	  
CONCLUSIONS	  	  and	  FUTURE	  RESEARCH	  
	  
•  EGR-­‐1	  protein	  expression	  is	  similar	  in	  cancerous	  (malignant)	  and	  in	  histologically	  normal	  
adjacent	  (benign)	  Sssues	  from	  both	  prostatectomy	  and	  biopsy	  Sssues.	  This	  supports	  the	  
concept	  of	  ﬁeld	  cancerizaSon	  and	  indicates	  a	  potenSal	  organ-­‐wide	  molecular	  change.	  	  
•  Future	  research	  includes	  improvements	  at	  the	  conceptual	  and	  technical	  level:	  	  
Ø  Increasing	  the	  number	  of	  cases	  and	  including	  disease-­‐free	  (age-­‐matched)	  prostate	  8ssues	  
Ø  Overcoming	  the	  autoﬂuorescence	  of	  prosta8c	  8ssues	  by	  the	  use	  of	  Alexa	  Fluor	  633-­‐conjugated	  2nd	  
an8bodies	  	  (far	  red)	  and	  increasing	  the	  resolu8on	  of	  detec8on	  by	  confocal	  microscopy	  
Ø  Design	  studies	  towards	  the	  clinical	  exploita8on	  of	  markers	  of	  ﬁeld	  canceriza8on.	  In	  par8cular,	  we	  
are	   interested	   in	   developing	   non-­‐invasive	   assessment	   methods	   using	   novel	   and	   upcoming	  
technologies,	  including	  targeted	  nanopar8cle	  imaging	  modali8es	  
SIGNIFICANCE	  of	  RESEARCH	  
	  
Markers	  of	  ﬁeld	  cancerizaSon:	  	  
•  PotenSal	  to	  lower	  persistently	  high	  false-­‐negaSve	  detecSon	  rate	  by	  expanding	  
the	  target	  region.	  
•  PotenSal	   for	   a	   new	   targeted	   repeat	   biopsy	   for	   paSents	   with	   high	   serum	  
prostate	  speciﬁc	  anSgen	  (PSA)	  but	  negaSve	  biopsy.	  
•  PotenSal	  to	  improve	  clinical	  decision	  making,	  such	  as	  surgical	   intervenSon	  vs.	  
acSve	  surveillance.	  
Figure	  9.	  Biopsy	  cores	  miss	  the	  two	  
small	   cancer	   loci	   (white	   irregular	  
structures) ,	   whi le	   the	   ﬁeld	  
associated	   with	   the	   caner	   loci	   is	  




















































































Figure	  7.	  Depic7on	  of	  the	  region	  
of	  interest	  analysis	  mode.	  
Figure	  8.	  Representa7ve	  immunoﬂuorescent	  detec7on	  (green)	  of	  EGR-­‐1	  in	  two	  cases	  of	  malignant	  and	  benign	  7ssues	  of	  
prostatectomies	  and	  biopsies.	  
Graphs	   3	   and	   4.	   Quan7ta7ve	   immunoﬂuorescence	   data	   of	   EGR-­‐1	   in	   human	   malignant	   and	   benign	   prostate	  
7ssues	  from	  prostatectomies	  and	  biopsies	  by	  whole	  image	  and	  region	  of	  interest	  analyses.	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